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A B S T R A C T
Introduction: Depression is a common reason for patients to consult homeopaths. This review aims to assess the
eﬃcacy, eﬀectiveness and safety of homeopathy in depression.
Methods: Thirty databases/sources were used to identify studies reporting on homeopathy in depression, pub-
lished between 1982 and 2016. Studies were assessed for their risk of bias, model validity, aspect of homeopathy
and comparator.
Results: Eighteen studies assessing homeopathy in depression were identiﬁed. Two double-blind placebo-con-
trolled trials of homeopathic medicinal products (HMPs) for depression were assessed. The ﬁrst trial (N=91)
with high risk of bias found HMPs were non-inferior to ﬂuoxetine at 4 (p=0.654) and 8 weeks (p=0.965);
whereas the second trial (N= 133), with low risk of bias, found HMPs was comparable to ﬂuoxetine (p= 0.082)
and superior to placebo (p < 0.005) at 6 weeks. The remaining research had unclear/high risk of bias. A non-
placebo-controlled RCT found standardised treatment by homeopaths comparable to ﬂuvoxamine; a cohort
study of patients receiving treatment provided by GPs practising homeopathy reported signiﬁcantly lower
consumption of psychotropic drugs and improved depression; and patient-reported outcomes showed at least
moderate improvement in 10 of 12 uncontrolled studies. Fourteen trials provided safety data. All adverse events
were mild or moderate, and transient. No evidence suggested treatment was unsafe.
Conclusions: Limited evidence from two placebo-controlled double-blinded trials suggests HMPs might be
comparable to antidepressants and superior to placebo in depression, and patients treated by homeopaths report
improvement in depression. Overall, the evidence gives a potentially promising risk beneﬁt ratio. There is a need
for additional high quality studies.
1. Introduction
Depression is the third most common burden of disease worldwide
and is expected to become the leading burden of disease by 2030 [1].
The National Institute for Health and Clinical Excellence primarily re-
commends non-medical interventions such as cognitive behavioural
therapy in sub-threshold, mild and moderate depression as the ﬁrst line
treatment [2]. If these interventions are ineﬀective or the depression is
severe, antidepressant drugs are recommended. These treatment op-
tions help some but not all patients, there is concern about the overuse
of psychotropic drugs, and insuﬃcient alternatives. Some patients seek
alternative treatment options, and depression and other mental health
problems are among the most common reasons why patients seek ho-
meopathy [3,4]. Homeopathy is controversial in some quarters, but
despite this there is widespread use. A recent systematic review of 12-
month prevalence of homeopathy use in eleven countries (USA, UK,
Australia, Israel, Canada, Switzerland, Norway, Germany, South Korea,
Japan and Singapore) found that a small but signiﬁcant percentage of
these general populations consulted homeopaths and/or purchased
over-the-counter homeopathic medicines [5].
According to the MeSH term (E02.190.388) homeopathy is “a
system of therapeutics founded by Samuel Hahnemann (1755–1843),
based on the Law of Similars where ‘like cures like’. Diseases are treated
by highly diluted substances that cause, in healthy persons, symptoms
like those of the disease to be treated.” These substances, which are
referred to as Homeopathic Medicinal Products (HMPs), are regulated
through European Directives for medicinal products [6]. Treatment by
homeopaths involves consultations and subsequent prescription of in-
dividually tailored HMPs based on information obtained during con-
sultations. Standardised medicines for clinical complaints also exist.
There is a need to assess the existing research evidence for ho-
meopathy in depression due to the prevalence of depression in all
countries worldwide, the limited eﬀect of existing recommended in-
terventions, and the fact that patients use homeopathy as an alternative
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or a complement to conventional treatment. One systematic review
assessing research evidence for homeopathy in depression concluded
that there was limited evidence due to a lack of high quality trials [7].
Another review on homeopathy in psychiatric conditions, which in-
cluded only randomised placebo-controlled trials found none reporting
on depression [8]. The aim of this review is to update these previous
reviews and to assess the evidence for the eﬃcacy, eﬀectiveness and
safety of homeopathy in patients with depression. The ﬁrst draft of this
updated review was published in the ﬁrst author’s (PV) PhD Thesis [9].
This article presents the results of our updated review.
2. Methods
2.1. Search strategy
A systematic search of 30 databases and other sources was carried
out, including e.g. CINAHL, Cochrane Library, EMBASE, PubMed/
MEDLINE, and PsycINFO (Appendix A). Literature searches were car-
ried out by one researcher (PV) from 9 to 12.08.2012, with update
searches on 15.11.2013 and 05.07.2016. A second researcher (PF)
checked all searches and found them to be appropriate. Screening of all
articles (at titles/abstract and full-text level) was carried out by both
researchers. Reference lists were checked and 44 researchers in 19
countries were contacted to identify additional titles.
Inclusion criteria were studies reporting on homeopathic treatment
of patients with diagnosed or self-reported depression between 1982
and July 2016. In a previous extensive literature search, the authors
found that most homeopathy trials were published after 1982, and none
published prior to 1982 reported on mental health problems [10]. We
therefore limited our search to studies published after 1982. This date
also coincides with the time when selective serotonin reuptake in-
hibitors (SSRIs), the most commonly prescribed antidepressants to date,
came onto the market. No language limitations were set. Exclusion
criteria were studies not reporting outcomes in patients suﬀering from
depression as the primary focus; bipolar disorder; HMPs used in an-
throposophical medicine, administered as injections or concentrations
higher than 1:10,000 or one 100th of the smallest dose used in con-
ventional drugs (and therefore not available without a prescription in
EU/EEA countries); animal studies; studies with less than 10 partici-
pants; conference abstracts; and reports presented in books.
Search strategies were adapted to each database, using variations of
the words “homeopathy,” “homeopathic drugs,” “potentised,” “de-
pression,” “depressive disorder,” “dysthymia” and “dysthymic dis-
order”, using wildcard symbols, and Boolean operators to combine
terms.
The PICO may be describes as follows: Participants were patients
with diagnosed or self-reported depression. The intervention was
treatment provided by homeopaths or use of homeopathic medicinal
products (HMPs). The comparator could be placebo, other depression
medication or other depression treatment, waiting list, or no com-
parator. Outcomes were primary outcomes focusing on depression.
2.2. Data extraction and analysis
Articles were translated where necessary (Farsi n= 1, Portuguese
n=1, Spanish n=1). Data were extracted, appraised and analysed by
one author (PV) and checked by a second (PF). Consensus of under-
standing was reached for all studies.
Data extracted from identiﬁed articles were input according to the
Cochrane Consumers and Communication Review Group’s data ex-
traction template. Risk of bias was assessed according to the Cochrane
Collaboration’s guidelines, focusing on the main outcome measure for
each trial [11]. Within-study publication bias, also referred to as out-
come reporting bias or selective reporting bias, was reported for each
included study. We also considered the potential risk of between-study
publication bias. Controlled and uncontrolled studies were reported
according to the STROBE statement [12]. We planned to carry out a
meta-analysis in the event that the results of at least two trials could be
presented at an aggregated level. This was however not carried out as
we only found analysable data from two trials of which one was a non-
inferiority trial and the other a superiority trial.
An important question when assessing research evidence is whether
individual studies provide the “best possible” outcome that could be
expected with the tested intervention in the particular ﬁeld of research.
An assessment of the model validity of studies, the degree to which the
design and setting corresponds to “best practice” [13], was therefore
determined using recommendations put forward by Mathie et al. [14].
2.3. Type of studies
The identiﬁed studies were categorised into three groups and de-
scribed separately: those assessing the eﬃcacy of HMPs; those assessing
the eﬀectiveness of treatment by homeopaths; and those describing the
outcomes of patients treated by homeopaths.
Randomised double-blinded placebo-controlled trials were used to
assess the eﬃcacy of HMPs. To assess the eﬀectiveness of treatment
provided by homeopaths (consultations and HMPs), non-blinded ran-
domised controlled trials (RCTs) and observational studies (cohort and
case control studies) were used. Uncontrolled studies (UCs) (including
surveys) were used to assess outcomes during and after treatment, but
not as evidence of causal links. Where possible, results were reported in
an aggregated form, summarising outcomes for more than one study.
Where p-values were reported, ≤ 0.05 was considered statistically
signiﬁcant. To assess the safety of homeopathy, adverse event reporting
from all three groups was considered.
3. Results
3.1. Search results
Thirty databases and other sources identiﬁed 3692 titles. After ad-
dition of 31 titles identiﬁed through reference lists (n= 24), contact
with other researchers (n=7), and removal of duplicates, 2649 titles
were screened. Results of the literature search are presented in Fig. 1,
reported according to PRISMA [15]. Eighteen original studies were
identiﬁed, including three placebo-controlled double-blind trials
[16–18], a non-placebo controlled randomised trial [19], a non-ran-
domised trial [20], an observational cohort [21], and 12 uncontrolled
studies and surveys [22–33].
3.2. The eﬃcacy of homeopathic medicinal products
The eﬃcacy of homeopathic medicinal products prescribed for pa-
tients suﬀering from diagnosed depression was assessed in three RCTs
(Table 1) [16–18].
In the most recently published placebo-controlled double-blinded
double-dummy trial, the eﬃcacy of individualised HMPs was compared
to ﬂuoxetine and placebo in 133 menopausal women suﬀering from
moderate to severe diagnosed depression [18]. All women underwent a
full consultation with a homeopath who prescribed an individually
adapted HMP, with follow-up consultations at 4 and 6 weeks. Patients
received either an HMP plus a placebo for ﬂuoxetine (n=44); ﬂuox-
etine and placebo for an HMP (n=46); or placebo for both (n=43).
HMPs were prescribed daily in liquid C30 or C200 potency. Fluoxetine-
hydrochlorine 20mg was increased to 40mg after 4 weeks in case of
non-response. The intention-to-treat analysis showed a 5.0 point dif-
ference in favour of HMPs compared to placebo, measured on the 17-
item Hamilton Rating Scale for Depression (HRSD) at 6 weeks
(p < 0.001). Fluoxetine was better than placebo by 3.2 points
(p < 0.001). Results were clinically signiﬁcant (minimum 3.0 points).
Diﬀerences between homeopathy and ﬂuoxetine were non-signiﬁcant
(p= 0.082). Response rates (min. 50% HRSD decrease) at 6 weeks were
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better for homeopathy (54.4%) and ﬂuoxetine (41.3%), compared to
placebo (11.6%) (p < 0.001), whereas diﬀerences in remission rates
(min. 7 point HRSD reduction) were not statistically signiﬁcant (ho-
meopathy 15.9%, ﬂuoxetine 15.2%, placebo 4.7%, p= 0.194). Sec-
ondary outcomes included the Beck Depression Inventory (BDI), with
non-signiﬁcant diﬀerences (p=0.130); and the Greene Climacteric
Scale (GS), measuring vasomotor, somatic and psychological symptoms
including anxiety and depression, with signiﬁcant diﬀerences
(p=0.002), where HMPs were superior to placebo, but not sig-
niﬁcantly superior to ﬂuoxetine. Fluoxetine was not signiﬁcantly better
than placebo. There were no serious adverse events due to homeopathy.
The prevalence of non-serious adverse events was similar in the three
groups and included insomnia (n= 6, 13.6%), dyspepsia (n=6,
13.6%), nausea (n=5, 11.4%), fatigue (n=5, 11.4%), anxiety (n=4,
9.1%), dizziness (n=4, 9.1%), diarrhoea (n= 3, 6.8%), headache
(n=3, 6.8%), and constipation (n=2, 4.5%). The study was well
described, it included a sample size calculation and multiple imputation
was used for missing data. The risk of bias was low (Fig. 2) and the trial
had acceptable model validity (Fig. 3).
A non-inferiority placebo-controlled double-dummy trial included
91 participants diagnosed with acute moderate to severe depression
receiving either individually prescribed HMPs (Q-potencies daily) to-
gether with a placebo for ﬂuoxetine; or ﬂuoxetine (20mg daily, in-
creased to 40mg after 4 weeks if no response) together with a placebo
for HMPs [16]. All patients underwent the same medical and homeo-
pathic assessment. Both groups (homeopathy n=48, ﬂuoxetine
n=43) improved over time (p < 0.001) on the Montgomery Åsberg
Depression Rating Scale (MADRS), with no signiﬁcant between group
diﬀerences at 4 weeks (95% CI -6.95, 0.86, p=0.65) and 8 weeks (95%
CI -6.05, 0.77, p=0.97). The pre-ﬁxed margin of non-inferiority was
(Δ) 1.45, which was 1/3-1/2 of the advantage of ﬂuoxetine over pla-
cebo, and the minimum considered of clinical relevance. Secondary
outcomes were also similar in the two groups, including response rates
(min. 50% MADRS reduction) at 4 weeks (ﬂuoxetine 63.9%, homeop-
athy 65.8%) and 8 weeks (ﬂuoxetine 84.6%, homeopathy 82.8%); and
remission rates (MADRS < 11) at 4 weeks (ﬂuoxetine 47.2%, ho-
meopathy 55.3%, p=0.42) and 8 weeks (ﬂuoxetine 76.9%, homeop-
athy 72.4%, p=0.72). The sample size was suﬃcient to establish non-
inferiority of homeopathy compared to ﬂuoxetine. The trial was well
described, although only percentages (and not numbers) were provided
for secondary outcomes (response & remission rates). The trial had high
risk of bias due to high attrition rates (40% in both trial arms), and
acceptable model validity.
The third randomised placebo-controlled trial had low risk of bias,
but recruited only 44 out of 228 participants and was therefore un-
derpowered and statistical tests were not carried out [17].
3.3. The eﬀectiveness of treatment provided by homeopaths
The eﬀectiveness of treatment provided by homeopaths was as-
sessed in a non-placebo randomised controlled trial [19], a non-ran-
domised trial [20], and an observational cohort [21] (Table 2).
In a non-placebo controlled randomised trial including 211 meno-
pausal women with self-reported depression, the eﬀectiveness of a
standardised homeopathic medicinal product (Ignatia Homaccord
[Ignatia amara & Moschus moschiferus], Heel GmbH) (n=110) pre-
scribed daily for all patients was compared to ﬂuvoxamine (n=101)
[19]. Reduction in scores in the two groups at 6 weeks were comparable
when measured on the Hamilton Depression Rating Scale (HDRS)
(homeopathy 61%, ﬂuoxetine 58%), as well as the Beck Depression
Inventory (BDI) (homeopathy 66%, ﬂuoxetine 65%). Response rates
(min. 50% improvement) were also comparable (homeopathy 68%,
ﬂuoxetine 65%). All between group diﬀerences were not statistically
signiﬁcant (p > 0.05). Results must be interpreted with caution, due to
Fig. 1. Flow of information in the systematic review.
P. Viksveen et al. (XURSHDQ-RXUQDORI,QWHJUDWLYH0HGLFLQH²

Table 1
Randomised controlled trials comparing homeopathic medicines to placebo for depression (main outcome).
Author, year,
country
RCT Design Sample, recruitment, setting Intervention Control Outcome measures Results
Adler et al. 2011
[16]
Brazil
Non-inferiority
trial
2 arms double-
blinded, double-
dummy, placebo-
controlled,
Moderate to severe depression (DSM-IV
according to SCID+MADRS score
min.15)
N=91
Homeopathic medicine+ placebo for
ﬂuoxetine (H) n= 48
Fluoxetine+ placebo homeopathic
medicine (F) n= 43
Recruitment: MD referral within public
health system
Setting: Depression outpatient clinic
Homeopathic medicine (H) + placebo
for ﬂuoxetine-hydrochlorine, for 8
weeks, plus
consultations with a homeopath
Homeopath: 1
Fluoxetine-hydrochlorine (F) 20mg daily, for
8 weeks, increased to 40mg after 4 weeks if
no response+ placebo homeopathic medicine
for, plus consultations with a homeopath
Primary: MADRS
at 4 & 8 weeks
Secondary:
Response &
remission rates at 4
& 8 weeks
Tolerability at 4 & 8
weeks
Homeopathy non-inferior to
ﬂuoxetine at 4 and 8 weeks
Between group diﬀerence for mean
MADRS score non-signiﬁcant at 4
weeks (95% CI -6.95, 0.86, p= 0.65)
and
8 weeks (95% CI -6.05, 0.77,
p=0.97)
Time eﬀect for both groups
p < 0.001
Response rates for H / F were
comparable at:
4 weeks: 63.9% / 65.8%
8 weeks: 84.6% / 82.8%
Remission rates H / F were
comparable at:
4 weeks: 47.1% / 55.3%, p= 0.42
8 weeks: 76.9% / 72.4%, p= 0.72
Tolerability comparable
Adverse events (AE): H: 10.7%, F:
21.4% (p=0.28)
Discontinued due to AE: H: n= 3. F:
n=8 (p=0.07)
Excluded due to worsening: H: n= 5.
F: n= 1 (p= 0.21)
Adler et al. 2013,
Germany
[17]
Four-armed
placebo-controlled
trial*
Acute major depression (moderate
episode) (psychiatrist diagnosis,
depression degree HAM-D score 17-24)
N=44
Recruitment: outpatient practices, radio
& TV interviews, advertisement in
newspapers and underground trains
Setting: Integrative Medicine outpatient
clinic of the Charité – Universitäts-
medizin Berlin
Consultation with
homeopath+ homeopathic medicine (H)
daily
Homeopath: 1
Consultation with homeopath+Placebo
homeopathic medicine daily
Primary: HAM-D 6
weeks
Secondary:
HAM-D 2 & 4 weeks
SF-12 & BDI 2, 4 &
6 weeks
Adverse events
Treatment
expectations
Only 44 out of 223 recruited
Data only analysed descriptively
At 6 weeks: No relevant diﬀerences
between homeopathic medicines and
placebo on HAM-D and BDI
Adverse events:
H: n=19 (of 30), 63.3%. P: n= 9 (of
14), 64.3%
No serious adverse events & no suicide
ideation
Macías-Cortés
et al. 2013,
Mexico [18]
Placebo-controlled
trial double-
blinded, double-
dummy
Moderate to severe depression (diagnosed
according to DSM-IV, degree of
depression HRSD score 14-24) in peri-
and post-menopausal women
N=133
Recruitment: Internet advertisements,
community groups, liaison with health
professionals, posters at study site,
brochures for hospital population
Setting: Hospital Juárez de México,
Ministry of Health
Intervention (H): Homeopathic
medicine+ placebo for ﬂuoxetine, plus
consultations with a homeopath
n=44
Homeopath: 1
Control 1 (F): Fluoxetine +
placebo for homeopathic medicine, plus
consultations with a homeopath
n=46
Control 2 (P):
Placebo for Fluoxetine+placebo for
homeopathic medicine, plus consultations
with a homeopath n= 43
Primary: HRSD
(17-item)
4 & 6 weeks
Clinically
signiﬁcant: min. 3
points
Secondary:
Response: min.50%
decrease
Remission: 7 points
or less
BDI at 4 & 6 weeks
GS at 4 & 6 weeks
Adverse events 4 &
6 weeks
At 6 weeks:**
HRSD: Homeopathy better than
placebo by 5.0 points (p < 0.001)
Fluoxetine better than placebo by 3.2
points (p < 0.001)
BDI: No statistically signiﬁcant
diﬀerence
GS: Statistically signiﬁcant diﬀerences
(p= 0.002). Homeopathy better than
placebo, not better than ﬂuoxetine.
Fluoxetine not better than placebo.
Response 6 weeks (min.50% decrease
on HRSD):
H: 54.4%, F: 41.3%, P: 11.6%
(p < 0.001)
Remission at 6 weeks (min. 7 point
reduction on HRSD):
H: 15.9%, F: 15.2%, P: 4.7%
(continued on next page)
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methodological weaknesses resulting in high risk of bias. The trial had
inadequate model validity as the intervention was not based on the ‘like
treats like’ principle so a substantial number of homeopaths would not
support the choice of intervention for this group of patients.
In an observational cohort study, 710 depressed patients’ use of
psychotropic drugs was assessed over a time period of 12 months
(Table 2) [21]. Compared to patients treated by general practitioners
solely practising conventional medicine (GP-CM n=161), patients
treated by GPs mainly practising homeopathy (GP-Ho n=289) or
partially practising homeopathy (GP-Mx n=260), used signiﬁcantly
less psychotropic drugs (OR 0.29, 95% CI 0.19-0.44, p < 0.001; OR
0.62, 95% CI, 0.41-0.94, p=0.02). Results controlled for potential
confounding factors and baseline characteristics, and were not aﬀected
by depression severity. Similarly, the rate of clinical improvement
(HADS score< 9) was better in the GP-Ho group compared to the GP-
CM group (OR 1.70, 95% CI 1.10–2.87, p=0.05), but not when
comparing GP-Mx patients to GP-CM patients (OR 1.49, 95% CI
0.89–2.50, p=0.13). There was potential selection bias due to low
participation rates (45%), although this was similar across all three
groups and diﬀerences between participants and non-participants were
comparable. Baseline between group diﬀerences in anxiety and de-
pression severity and history of suicide attempt could explain some, but
not all between group diﬀerences in outcomes. Model validity was
uncertain.
A trial that was considered by the reviewers to be non-randomised,
suggested the combination of cognitive behavioural therapy (CBT) and
homeopathy, was more eﬀective than placebo or either treatment alone
[20]. Results should be interpreted with caution due to high risk of bias
(Fig. 4) and model validity was uncertain as it could not be assessed
(Fig. 5).
3.4. Outcomes during and after treatment provided by homeopaths
Twelve uncontrolled studies (Table 3) reported outcomes in a total
of 595 patients (median 33, range 22–201) during or after treatment
provided by homeopaths, including eight prospective uncontrolled
studies [23,26–29,31–33], three surveys [24,25,30], and a retro-
spective case series [22]. Studies were highly heterogeneous and could
only to a limited extent be presented in an aggregated form.
Six uncontrolled studies and surveys included 391 depressed pa-
tients (median 43, range 28–201) who were subsets of larger patient
groups with various diagnoses [24,28,30–33]. Patient-reported nu-
merical rating scales showed at least moderate improvement (+2, +3
or +4 on seven- and nine-point numerical rating scales) in 50% to 86%
of patients (median 67%), and slight or no improvement in 7% to 50%
of patients (median 22%) following individualised treatment provided
by homeopaths. The time point for outcome assessment varied con-
siderably (e.g. from 6 months to 7 years after treatment start), thereby
reducing the generalisability of results.
A study including 83 patients diagnosed with depression receiving
individualised treatment provided by homeopaths showed signiﬁcant
improvements at 3, 6, 9 and 12 months on the 17-point Hamilton
Depression Rating Scale (HDRS), Beck Depression Inventory (BDI), the
Clinical Global Impression (CGI-1) and Clinical Global Improvement
(CGI-2) (all at p= 0.001) [29]. At 12 months, 75% to 100% improve-
ment in HDRS scores was seen in 57.8% (n=48); 50% to<75% im-
provement in 20.5% (n= 17); 25% to<50% improvement in 2.4%
(n= 2); and 19.3% (n= 16) did not experience a signiﬁcant change.
Results were better for moderately and severely depressed patients,
compared to those suﬀering from mild depression.
A retrospective case series of 15 patients diagnosed with depression
found statistically signiﬁcant improvements on the Montgomery Åsberg
Depression Rating Scale (MADRS) at the 2nd (mean 7 weeks) and 3rd
(14.5 weeks) consultation (p < 0.001) [22]. A minimum improvement
of 50% was found in 14 out of 15 patients by the 3rd consultation.
The remaining four titles included two small prospective studies,Ta
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one with marked improvement in more than half the patients using the
SF-36 wellbeing questionnaire at 12 months [23], a second with im-
provement in depression in almost three quarters of patients after at
least 2 months [26], and a third with 10%–100% improvement in de-
pression severity after at least 2 months [25]. Results of the last study
are presented in the safety section [27].
All uncontrolled studies have a high risk of selection, performance
and detection bias, as there are no control groups and there is no
blinding of patients, practitioners and assessors (Fig. 6). Risk of re-
porting bias was considered to be low for most studies
[22–26,28,30–33]. Only two studies had low risk of attrition bias and
other forms of bias [22,29]. The remaining studies only provided lim-
ited information about depression and used outcome measures not
validated for depression, therefore leading to uncertain risk of attrition
bias and other forms of bias. A single study was considered to have
acceptable model validity [22] and one had inadequate model validity
[27] (Fig. 7). The remaining had overall uncertain model validity as
each of these had at least one unclear key domain (rationale, principles,
appropriate and sensitive outcome measure).
3.5. Safety of homeopathic medicines and treatment by homeopaths in
depression
Four controlled trials [16–19], a cohort study [21], and nine un-
controlled studies provided data relating to the safety of homeopathy
[22–24,27,29–33]. No serious adverse events were reported according
to NIH/NCI criteria (2010).
Adverse events in the homeopathy and ﬂuoxetine groups were
comparable in three placebo-controlled double-blinded trials [16–18].
No patient needed to interrupt treatment due to adverse events [18], or
adverse events were more common in the ﬂuoxetine (21.4%) than the
homeopathy (10.7%) group [16]; more patients discontinued treatment
due to adverse events in the ﬂuoxetine (n=8) than the homeopathy
(n= 3) group; and a greater number of patients randomised to ho-
meopathy (n=5) than ﬂuoxetine (n=1) were excluded from the trial
as a result of an intensiﬁcation of depressive symptoms. However, these
trials were not powered to assess adverse eﬀects and diﬀerences were
not statistically signiﬁcant. The cohort study did not detect statistically
signiﬁcant diﬀerences in the prevalence of self-reported injuries (GP-Ho
9.5%, GP-Mx 7.1%, GP-CM 14.8%) or suicide attempts (GP-Ho 1.5%,
GP-Mx 1.9%, GP-CM 5.0%) [21]. In the non-placebo RCT, the stan-
dardised HMP was better tolerated than ﬂuvoxamine, but no sig-
niﬁcance tests were presented [19].
One uncontrolled study identiﬁed mild to moderate adverse events
in 26% (n= 9) of patients [27]. Four studies did not identify any ad-
verse events [29], or any deterioration of health [30–32], whereas
others reported one [22,24], or two patients with slight deterioration
[33], or three that were not better or worse [23].
In summary, few adverse events or cases of deteriorated state of
health were reported and there was no evidence to suggest that treat-
ment provided by homeopaths for patients suﬀering from diagnosed or
self-reported depression was unsafe.
4. Discussion
This systematic review adds 17 original research studies to a pre-
vious systematic review [7], and includes only one title identiﬁed in the
previous review. This updated review adds to the evidence of the eﬃ-
cacy of HMPs and changes in patient-reported outcomes following
treatment provided by homeopaths. We cannot exclude the possibility
that some studies have been overlooked particularly as we excluded
conference abstracts from our search strategy. However, we reduced
the risk of between-studies publication bias through the use of several
large generic databases and smaller homeopathy- and CAM-speciﬁc
databases, by not setting any language limitations, and by contacting
experts in the ﬁeld in 19 countries. We consider it less likely that results
Fig. 2. Risk of bias assessment for RCTs comparing homeopathic medi-
cines to placebo for depression.
Risk of bias indications: Plus (+) = Low risk of bias. Question mark (?) =
Uncertain risk of bias. Minus (-) = High risk of bias.
* Adler et al. 2013a compared HMPs to placebo, Adler et al. 2013b compared
shorter to longer consultations.
Fig. 3. Model validity for RCTs comparing homeopathic medicines to
placebo for depression.
Model validity indications: Plus (+) = Acceptable model validity. Question
mark (?) = Uncertain model validity. Minus (-) = Inadequate model validity.
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Table 2
Observational studies and non-placebo trials assessing the eﬀectiveness of treatment by homeopaths.
Author, year,
country
Design Sample, treatment groups,
recruitment, setting
Intervention Control Outcome measures Results
Wasilewski 2004,
Poland [19]
Randomised controlled trial
comparing homeopathic
complex to anti-depressant
(no placebo control)
Depression in menopausal women,
N=211
(First depressive episode n= 135,
Recurrence n= 76)
Recruitment: unknown
Setting: Neuro-psychiatric clinic,
Łódź,
Standardised homeopathic
medicine (H) 2x daily
n= 110
Fluvoxamine (F) 50mg
3x daily
n= 101
HDRS & BDI at 6
weeks
No signiﬁcant between group diﬀerences in HDRS
and BDI scores at 6 weeks
Completion rates: H 91% (100 of 110), F 81% (82 of
101)
Reduction in depression scores at 6 weeks:
HDRS BDI Min. 50% better
H: 61% 66% 68% (n=68)
F: 58% 65% 65% (n=53)
All between group diﬀerences n.s. (p > 0.05)
Tolerability: Homeopathy signiﬁcantly better
tolerated than Fluvoxamine (p-value not reported).
Side-eﬀects of Fluvoxamine were especially nausea/
gastric symptoms (common side-eﬀects for F).
Drop-out due to side eﬀects: Homeopathy n= 2.
Fluvoxamine n= 12
Shukla et al.
2015,
India [20]
Unclear, most likely a non-
randomised trial with 4
groups
Depression (questionnaire, details
unknown)
N=208
Recruitment:
Colleges, clinics and Hospitals in
Allahabad
Group 1
Individualised homeopathic
medicine alone n=52
Group 2
CBT+ individualised
homeopathic medicine n= 52
Group 3
CBT alone (frequency unknown)
n= 52
Group 4
Placebo+ practitioner
consultations (type and frequency
unknown)
n= 52
Not speciﬁed
Time of assessment
possibly at 6 months
No outcome measures reported
Authors state that combined CBT+ individualised
homeopathic medicine was better compared to CBT
alone, homeopathy alone or placebo (p= 0.05)
Grimaldi-
Bensouda
et al. 2016,
France [21]
Observational cohort study Depression (ICD-9 + min. score of
9 on HADS)
N=710
Recruitment/ setting: GPs
randomly selected from the French
National Directory of Physicians in
primary care
Treatment by GP mainly
practising homeopathy (GP-Ho)
n= 289
Treatment by GP partially
practising homeopathy (GP-Mx)
n= 260
Treatment by GP not practising
homeopathy (GP-CM) n=161
Primary:
Consumption of
psychotropic drugs
over 12 months
Secondary:
HADS at 12 months
Self-reported injuries
& suicide attempts
GP-Ho group reported lower use of psychotropic
drugs over 12 months:
GP-Ho 50.0%, GP-Mx 63.5%, GP-CM 68.0%
Drug use compared to GP-CM:
GP-Ho: OR 0.29 (95% CI 0.19, 0.44, p < 0.001)
GP-Mx: OR 0.62 (95% CI 0.41, 0.94, p= 0.02)
(results not aﬀected by ADD severity)
Clinical improvement (HADS < 9) at 12
months, compared to GP-CM:
GP-Ho: OR 1.70 (95% CI 1.10, 2.87, p= 0.05)
GP-Mx: OR 1.49 (95% CI 0.89, 2.50, p= 0.13)
(controlled for confounders and baseline
characteristics)
Self-reported injuries/suicide attempts: GP-Ho
9.5% / 1.5% (p > 0.05),
GP-Mx 7.1% / 1.9% (p > 0.05), GP-CM 14.8% /
5.0% (p > 0.05)
ADD: Anxiety and depression disorders. HADS: Hospital Anxiety and Depression Scale. OR: Odds ratio. CBT: Cognitive behavioural therapy. SF-36: Short Form (36) Health Survey.
Mulimen: consists of Ambra grisea, Calcium carbonicum, Cimicifuga racemosa, Gelsemium sempervirens, Hypericum perforatum, Kalium carbonicum, Sepia oﬃcinalis, Urtica dioica.
HDRS: Hamilton Depression Rating Scale. BDI: Beck Depression Inventory.
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of unidentiﬁed studies would signiﬁcantly aﬀect the overall results, as
the results for non-English studies and studies published in non-peer-
reviewed journals suggested comparable results.
The review used a novel approach to the assimilation of evidence by
considering three diﬀerent types of evidence: those assessing the eﬃ-
cacy of HMPs; those assessing the eﬀectiveness of treatment by ho-
meopaths; and those describing the outcomes of patients treated by
homeopaths.
A weakness of the overall evidence is the limited extent to which
aggregated results can be presented due to the heterogeneity of studies.
Placebo-controlled RCTs can help answer the question of whether a
speciﬁc part of an intervention, in this case HMPs, are eﬀective to treat
depression. Pragmatic RCTs and cohort studies can be used to test the
eﬀectiveness of the “whole treatment package”, in this case treatment
provided by homeopaths for depressed patients. The evidence from two
placebo-controlled double-blinded trials, one with high and another
with low risk of bias, suggests that homeopathic medicines may be non-
inferior to ﬂuoxetine. These ﬁndings are supported by two studies as-
sessing the eﬀectiveness of treatment by homeopaths; an observational
study of GPs which found less use of psychotropic drugs and improved
results for patients consulting with GPs prescribing HMPs, and a non-
placebo RCT suggesting that the eﬀectiveness of a standardised ho-
meopathic medicine is comparable to the eﬀectiveness of an anti-
depressant. The results of these non-blinded studies must be interpreted
with caution as they were associated with high risk of bias. However, a
single placebo-controlled trial with low risk of bias found homeopathic
medicines were superior to placebo and the results were clinically
signiﬁcant.
The lack of controls and randomisation in uncontrolled studies
precludes any conclusions about the eﬀectiveness of interventions, but
provides evidence of patient-reported outcomes following treatment by
homeopaths. Most uncontrolled studies were small and had limitations
reducing the reliability of results: high or unclear risk of detection,
reporting and attrition bias due to no use of blinded assessors, in-
suﬃcient information on drop-out and non-responders, and with the
exception of two studies, outcome measures had not been validated for
depressed patients. Strengths of uncontrolled studies were that all ex-
cept one referred to patients with a diagnosis of depression, and de-
scribed their reported changes in depression symptoms in “real world”
practice [35]. Results showed at least moderate improvement in most
patients in 10 out of 12 studies, whereas one only reported changes in
symptoms and the other only adverse events. Model validity was un-
certain or inadequate for all except one uncontrolled study. It is
therefore not possible to say if the treatments are representative of “best
practice”.
Overall, the results should be interpreted with caution due to high
and unclear risk of bias for most dimensions in most trials and studies.
The highest quality evidence from a single randomised placebo-con-
trolled trial found HMPs were non-inferior to antidepressants and su-
perior to placebo. The remaining research evidence suggested that
HMPs were non-inferior to antidepressants or patients improved over
the duration of a treatment course provided by homeopaths. There was
no evidence to suggest treatment was harmful.
4.1. Comparison with other interventions and recommendations for future
research
“Talking therapies” and antidepressants remain the interventions
most commonly recommended for depressed patients by health
Fig. 4. Risk of bias assessment for observational studies and non-placebo
trials assessing the eﬀectiveness of treatment by homeopaths.
Risk of bias indications: Plus (+) = Low risk of bias. Question mark (?) =
Uncertain risk of bias. Minus (-) = High risk of bias.
Fig. 5. Model validity for RCTs comparing homeopathic medicines to
placebo for depression.
Model validity indications: Plus (+) = Acceptable model validity. Question
mark (?) = Uncertain model validity. Minus (-) = Inadequate model validity.
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Table 3
Uncontrolled studies and surveys reporting on patient outcomes during or after treatment provided by homeopaths.
Depression primary outcome measure
Author, year,
country
Design Sample, recruitment, setting Intervention Control Outcome measures Results
Adler et al. 2008,
Brazil [22]
Case series, retrospective All new patients diagnosed with
depression (DSM-IV according to
SCID) over a 10 month period
N=15
Onset of depression: median 3 years
(IQR 1-15, range 0-22)
Last episode lasting: median 7 months
(IQR 5-18, range 1-60)
Recruitment/setting: Homeopathy
clinic for depressive disorders,
Jundiaí, Brazil
Individualised homeopathy for up to 4
consultations:
10 diﬀerent homeopathic remedies
were prescribed
No other concurrent treatment
Homeopath: 1
Before to after
assessment
MADRS score
at ﬁrst three follow-up consultations
Remission rates
Patient-completed outcome measure
At 2nd & 3rd consultation:
Statistically signiﬁcant reduction in MADRS
scores
At 4th consultation: Insuﬃcient data to assess
scores
At 3rd consultation (mean 14-15 weeks):
> 50% decrease in MADRS scores in 14 of
15 patients (93%)
One patient referred for antidepressant drug
therapy
Attena et al. 2000,
Italy [23]
Prospective, uncontrolled
study
Diagnosed depression (out of 648
consecutive patients diagnosed with
sub-acute and chronic conditions)
n=24
Recruitment/setting: Private clinic
with three doctors practicing
unconventional medicine
Pluralist homeopathy (more than one
remedy at the time)
Follow-up at 3 and 6 months
Homeopaths: 3
Before to after
assessment
SF-36, question 2: How do you
evaluate your health 1 year after you
started treatment?
Questionnaire completed over the
telephone, called by researcher (not
practitioner)
1 year after started treatment:
Marked improvement: n= 13 (54.2%)
Moderate improvement: n=8 (33.3%)
No improvement/worse: n= 3 (12.5%)
Clover 2000, UK
[24]
Survey Diagnosed depression in patients with
carcinoma of the breast (from 1000
consecutive patients with various
complaints) n= 14
Recruitment: from GPs and hospital
doctors
Setting: Homeopathic hospital
outpatient clinic, Tunbridge Wells
Individualised homeopathic treatment:
Details of treatment unknown (study
period 12 months)
Homeopaths: Unknown (> 1)
Before to after
assessment
7-point numerical self-reported rating
scale at follow-up consultations
Completed by patient with a clinic
clerk after follow-up consultation in
the absence of a doctor or nurse
7-point NRS at follow-up consultation:
+3 n=9 64.3%
+2: n= 3 21.4%
+1: n= 1 7.1%
0: n=0 0.0%
−1: n= 1 7.1%
−2/-3/-4: n= 0 0.0%
+ improvement, - deterioration (see
footnote)
Response rate at follow-up consultations
(n=2500):
55% (n=1372), no response 45% (n=822)
Response rate for depressed patients not
reported.
Dempster 1998, UK
[25]
Survey of random
selection of patients,
retrospective
Diagnosed depression N=12
Depression n= 8
Mild depression n= 2
Post-natal depression n=2
Recruitment: from GPs
Setting: NHS GP practice, West
Yorkshire
Individualised homeopathic treatment
in a single practice, treatment for
min.1 month
Homeopath: 1
Before to after
assessment
Self-reported improvement in
depression given in percent,
assessment 2-36 months after
treatment
Postal questionnaire completed by
patient
Improvement in depression:
Median 85%, mode 90% (n=4).
Interquartile range 55-90%. Range 10%-
100%
Improvement long-standing depression
(min.4 yrs) (n=5): 30%, 80%, 80%, 90%,
100%
Improvement recently developed
depression
(max.4 months) (n=4): 60%, 90%, 90%,
100%
8 of 11 patients stopped their medication (for
depression n= 6, uncertain n= 2) (one was
not taking any medication)
(continued on next page)
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Table 3 (continued)
Depression primary outcome measure
Author, year,
country
Design Sample, recruitment, setting Intervention Control Outcome measures Results
Hechavarria Torres
et al. 2014, Cuba
[26]
Uncontrolled study, most
probably prospective
Diagnosed depression (ICD-10)
(suicidal patients excluded)
n=35
Recruitment: unclear
Setting: Center for Development of
Natural and Traditional Medicine
Teaching Hospital General of
Santiago de Cuba
Individualised homeopathic treatment,
no concurrent conventional treatment,
but behavioural support (unspeciﬁed),
treatment for
min.2 months
Number of homeopaths not speciﬁed
Before to after
assessment
Assessment by a specialist from
before to after therapy, with response
categories:
A) Improved: symptoms disappear/
decline in number
B) Unchanged
C) Worse: symptoms increased in
number or intensity
Improvement in depression:
No depression: 74.3% (26 of 35 patients)
Improved symptoms: 73.4% (163 of 222)
including:
depression, inability to feel/enjoy, thoughts
of death/suicide, hopelessness, feelings of
worthlessness, self-reproach/guilt,
hypochondria and/or anxiety, sleep
disturbances, tiredness/fatigue
Mahmoudian 2015,
Iran [27]
Reported as “qualitative”,
but corresponds better to
an uncontrolled study
Chronic depression in war veterans
n=35
Recruitment: not reported
Setting: not reported
Standardised Natrium muriaticum 30C
to all participants, followed by
individualised homeopathic treatment
Homeopaths: not reported
Before to after
assessment
Aggravations: increase in previous
symptoms or appearance of new
symptoms
No eﬀectiveness outcomes
No eﬀectiveness outcomes
Aggravations: Mild to moderate: n= 9
(26%) including:
Headache (n= 3). desquamation skin lesions
(n=2),
anger (n= 2), anxiety (n=1), “obstinacy”
with family (n= 1)
Missing data: n= 7 (20.0%) due to
“inadequate information”
Mathie & Robinson
2006, UK [28]
Uncontrolled study,
prospective
Diagnosed depression (of 961
consecutive patients with various
complaints)
n=55
Recruitment: For NHS GPs (n=10)
patients attended their doctor in the
normal way; self-referral for private
practitioners (n= 2)
Setting: 10 NHS and 2 private
homeopathy GP practices, in England
and Scotland
Individualised homeopathic treatment
Homeopaths: 14
Before to after
assessment
7-point numerical self-reported rating
scale at last follow-up consultation,
max. 6 months
Patient-completed outcome at
consultation with homeopath
7-point NRS at latest follow-up
consultation (n= 55):
Major or moderate improvement (+2 or +3):
n= 35, 63.6%
Data not given for mild improvement (+1),
no change/unsure (0) and deterioration (-1/-
2/-3)
Participants: With follow-up n=55. Drop-
out n= 2
Oberai et al. 2013,
India [29]
Uncontrolled study,
prospective
Diagnosed depression (ICD-10
criteria, min. 2 typical symptoms +
2 common symptoms, excluded if
min. 25% improvement in HDRS after
1 week of placebo)
n=83
Onset of depression episode:
mean 1.92 years (SD 1.02)
Recruitment: Patients admitted to
the institute indoor patient
department
Setting: Central Research Institute,
Kottayam, Kerala
Individualised homeopathic treatment,
6 months
Number of homeopaths not speciﬁed
Before, during &
after assessment
Primary:
HDRS at 0, 3, 6 & 12 months
Secondary:
BDI, CGI-1, CGI-2
at 0, 3, 6 & 12 months
Adverse events
Outcome measures completed by
patients and collected by
investigators and consultant
psychiatrist
Primary: HDRS baseline (mean, SD):
Baseline: 17.98 (4.9). 12 months: 5.8 (5.9)
HDRS 0, 3, 6 & 12 months (repeated Measure
ANOVA): p=0.001. Eﬀect size= 0.74
Secondary:
BDI (mean SD): Baseline: 23.4 (6.9) 12
months: 7.1 (8.7)
BDI 0, 3, 6 & 12 months (repeated Measure
ANOVA):
p=0.001. Eﬀect size= 0.72
CGI-1 (median, IQR): Baseline: 4 (3.2-5), 12
months: 1 (1-2)
CGI-1 0, 3, 6 & 12 months (Friedman’s tests):
p=0.001. Eﬀect size: 0.82
CGI-2 (median, IQR): 3 months: 2 (2-3). 12
months: 1 (1-1)
CGI-2 3, 6 & 12 months (Friedman’s tests):
p=0.001. Eﬀect size: 0.79
Adverse events: None
(continued on next page)
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Table 3 (continued)
Depression primary outcome measure
Author, year,
country
Design Sample, recruitment, setting Intervention Control Outcome measures Results
Richardson 2001, UK
[30]
Survey Diagnosed depression (out of 1100
consecutive medically diagnosed
patients with various complaints)
n=30
Recruitment: from GPs
Setting: Department of homeopathic
medicine, Liverpool
Individualised homeopathic treatment,
mean 3.7 consultations (min.3), study
period
1 year
Homeopaths: 4?
Before to after
assessment
GHHOS (self-reported) after
treatment, after mean 3.7
consultations (min. 3)
(study period 1 year)
Patient-completed outcome handed
to receptionist, clinic doctor
completed a separate form recording
the outcome score (unclear
procedure)
GHOOS after treatment (min. 3
consultations, mean 3.7):
+2/+3/+4: n= 15 50.0%
+3/+4: n= 8 26.7%
+2: n= 7 23.3%
+1/0: n=15 50.0%
−1/-2/-3/-4: n= 0 0.0%
+ improvement, - deterioration (see
footnote)
Participants:
Response rate for depressed patients not
reported.
Only patients with follow-up consultations
included. Number of patients with no follow-
up consultation not reported.
Sevar 2000, UK [31] Uncontrolled study,
prospective
Diagnosed depression (out of 829
consecutive medically diagnosed
patients with various complaints)
n=64
Recruitment: uncertain
Setting: Private MD homeopathy
clinic, Cumbria
Individualised homeopathic treatment:
First consultation 75minutes, follow-
up 30minutes
Homeopaths: 1
Before to after
assessment
GHHOS (self-reported) after
treatment, assessment period 6
months – 7 years
Patient-reported outcome, data
collected by homeopath
GHOOS after treatment (range 6 months –
7 years):
+3/+4: n= 40 62.5%
+2: n= 5 7.8%
+1/0: n=10 15.6%
−1/-2/-3/-4: n= 0 0.0%
Unknown: n= 9 14.1%
+ improvement, - deterioration (see
footnote)
The 40 patients who experienced
considerable improvement, were able to
discontinue antidepressants
Participants:
Response rate 86% (n=55), No response
14% (n=9)
Sevar 2005, UK [32] Uncontrolled study,
prospective
Diagnosed depression (out of 455
consecutive medically diagnosed
patients with various complaints)
n=27
Recruitment: uncertain
Setting: Private MD homeopathy
clinic, Cumbria
Individualised homeopathic treatment:
First consultation 75minutes, follow-
up 45minutes (1st) or 30minutes
(other), mean 11 months (min. 6),
mean 2.4 consultations (all 455
patients)
Homeopaths: 1
Before to after
assessment
GHHOS after treatment,
mean 11 months (min. 6)
Combined patient- and clinician-
reported outcome
GHOOS after treatment (mean 11 months,
min. 6):
+4: n= 1 3.7%
+3: n= 16 59.3%
+2: n= 4 14.8%
+1: n= 1 3.7%
0: n=5 18.5%
−1/-2/-3/-4: n= 0 0.0%
Unknown: n= 0 0.0%
+ indicates improvement,
- indicates deterioration (see footnote)
14 patients (52%) were able to signiﬁcantly
reduce or discontinue antidepressants
Participants: Response rate 100% (n=27)
(continued on next page)
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Table 3 (continued)
Depression primary outcome measure
Author, year,
country
Design Sample, recruitment, setting Intervention Control Outcome measures Results
Spence et al. 2005,
UK [33]
Uncontrolled study,
prospective
Diagnosed depression (ICD-10, from
6888 consecutive diagnosed patients
in a university-hospital outpatient
clinic)
N=201
Recruitment: from GPs and hospital
specialist consultants
Setting: NHS university homeopathic
hospital outpatient clinic, Bristol
Individualised homeopathic treatment:
First consultation 45minutes, follow-
up 15minutes, mean total 3.6
consultations (for all patients), study
period 6 years
Homeopaths: 12
Before to after
assessment
7-point numerical self-reported rating
scale at follow-up consultations,
length not given (study period 6
years)
Patient-reported outcome, data
collected by homeopath
7-point NRS after mean 3.6 consultations:
+3 n=38 18.9%
+2: n= 69 34.3%
+1: n= 36 17.9%
0: n=46 22.9%
−1: n= 2 1.0%
−2/-3/-4: n= 0 0.0%
+ improvement, - deterioration (see
footnote)
Participants:
5% were unable to score (n= 8) or the results
were inﬂuenced by other factors (e.g. other
treatment) (n= 2)
Adler et al. [22]: SCID: Structured Clinical Interview. IQR: Interquartile range. MADRS: Montgomery & Åsberg Depression Rating Scale. Clover (2000): 7-point NRS: 7-point Numerical Rating: +3 Much better, +2 Better/
Moderately better, +1 Slightly better, 0 No change, -1 Slightly worse, -2 Worse/Moderately worse, -3 Much worse.
Mathie & Robinson [28]: 7-point NRS: 7-point Numerical Rating Scale: +3 Much better, +2 Better/Moderately better, +1 Slightly better, 0 No change, -1 Slightly worse, -2 Worse/Moderately worse, -3 Much worse.
Oberai et al. [29]: IQR: Interquartile range. NHS: National Health Service. HDRS: Hamilton Depression Rating Scale (17-point). BDI: Beck Depression Inventory (21-point). CGI-1: Clinical Global Impression (scale 1–7).
CGI-2: Clinical Global Improvement (scale 1–7).
Richardson [30], Sevar [31]: GHHOS: Glasgow Hospital Homeopathic Outcomes Scale, 9-point numerical rating scale including +4 Cured/Back to normal, +3 Major Improvement, +2 Moderate improvement, aﬀecting
daily living, +1 Slight improvement, no eﬀect on daily living, 0 No change/Unsure, -1 Slight deterioration, no eﬀect on daily living, -2 Moderate deterioration, aﬀecting daily living, -3 Major deterioration.
-4 Disastrous deterioration.
Sevar [32]: NHS: National Health Service. GHHOS: Glasgow Hospital Homeopathic Outcomes Scale, 9-point numerical rating scale including +4 Cured/Back to normal, +3 Major Improvement.
+2 Moderate improvement, aﬀecting daily living, +1 Slight improvement, no eﬀect on daily living, 0 No change/Unsure, -1 Slight deterioration, no eﬀect on daily living, -2 Moderate deterioration, aﬀecting daily living.
-3 Major deterioration,-4 Disastrous deterioration.
Spence et al. [33]: NHS: National Health Service. 7-point NRS: 7-point Numerical Rating Scale: +3 Major improvement, +2 Moderate improvement, +1 Mild improvement, 0 No change or unsure, -1 Mild deterioration,
-2 Moderate deterioration, -3 Major deterioration.
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services. The research evidence presented in this systematic review
suggested HMPs might be at least as eﬀective as some commonly used
antidepressants. Systematic reviews assessing antidepressants have
been associated with small eﬀect sizes [e.g. [36]], with only clinically
signiﬁcant eﬀects for patients suﬀering from very severe depression
[34]. Does this mean that the eﬀect of HMPs in the reported homeop-
athy trials, were placebo eﬀects? Such an assumption was negated in
one of the trials identifying a statistically and clinically signiﬁcant
eﬀect of HMPs compared to placebo. Further research is needed in
order to conﬁrm whether HMPs are superior to placebo and comparable
or superior to commonly used antidepressants, and whether they are
safe. Such results would also need to be carried out in diﬀerent groups
of patients, including diﬀerent depression severity groups (mild, mod-
erate and severe depression), diﬀerent age groups (e.g. adolescents,
elderly), and patients with various comorbidities (e.g. pain, cancer), if
results are to be generalised to diﬀerent populations of depressed
Fig. 6. Risk of bias assessment for uncontrolled studies.
Risk of bias indications: Plus (+) = Low risk of bias. Question mark (?) = Uncertain risk of bias. Minus (-) = High risk of bias.
Fig. 7. Model validity for uncontrolled studies.
Model validity indications: Plus (+) = Acceptable model validity. Question mark (?) = Uncertain model validity. Minus (-) = Inadequate model validity.
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patients. Moreover, pragmatic RCTs are needed in order to test the
eﬀectiveness and cost-eﬀectiveness of the “whole treatment package”
provided by homeopaths, including consultations and medication,
compared to commonly used interventions such as consultations with
psychologists or with GPs who prescribe antidepressants.
Although some authors report up to moderate eﬀect sizes of psy-
chological interventions compared to waitlist or usual care controls for
patients with depression [e.g. [37]], the “true” eﬀect is commonly
overestimated [e.g. [38]], and some authors found no signiﬁcant dif-
ferences when comparing “talking therapies” such as psychotherapy to
antidepressants, or when comparing combinations of psychotherapy
and antidepressants to antidepressants alone [34]. No RCTs comparing
the eﬀectiveness of the “whole treatment package” including con-
sultations and individually adapted medication provided by homeo-
paths to usual care were identiﬁed in the review. This research is re-
quired in order to assess the eﬀectiveness of homeopathy in “real world
practice” as an alternative or an adjunctive intervention to “talking
therapy” interventions and antidepressant treatment.
The risk beneﬁt ratio should also be considered for clinical decision
making. Transient mild to moderate adverse events were identiﬁed.
Although the studies included in our depression review were not
powered to assess adverse events, there was no evidence to suggest the
intervention was unsafe. Further suﬃciently powered research should
look into the safety of homeopathic treatment.
5. Conclusions
The existing limited research evidence suggests that the eﬀective-
ness of homeopathic medicinal products for depressed patients is
comparable to some antidepressants and superior to placebo, with
clinically signiﬁcant eﬀects. A signiﬁcant proportion of patients report
improvements in depression following treatment provided by homeo-
paths in uncontrolled studies and surveys. No evidence suggested
treatment was unsafe. However, further research is still needed to test
the eﬃcacy of homeopathic medicinal products, the eﬀectiveness of
treatment provided by homeopaths, and the safety of the intervention.
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